Skip to main content
Home > Week in Review > Other News

Chronological Index of : Other News

 Current Issue
  • BioMotiv, Optikira LLC, University of California, University of Washington endocrine/metabolic, ophthalmic news

    BioMotiv LLC, Cleveland, Ohio Optikira LLC, Cleveland, Ohio University of California, San Francisco, Calif. University of Washington, Seattle, Wash. Business: Endocrine/Metabolic, Ophthalmic Drug development accelerator…

    Published on 2/9/2015
  • Invitae, Myriad Genetics, Pathway Genomics diagnostic news

    Invitae Corp., San Francisco, Calif. Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Pathway Genomics Corp., San Diego, Calif. Business: Diagnostic Myriad reached settlements to dismiss litigation with Invitae …

    Published on 2/9/2015
  • Pfizer, China National Pharmaceutical Group Corp. supply/service news

    Pfizer Inc. (NYSE:PFE), New York, N.Y. China National Pharmaceutical Group Corp. (Sinopharm), Beijing, China Business: Supply/Service Under an initial three-year agreement, Pfizers Pfizer Investment Co. Ltd. unit and …

    Published on 2/9/2015
  • Ablynx, GlaxoSmithKline antibodies news

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Antibodies Ablynx said the Board of Appeal confirmed a 2010 decision from the Opposition Division of the …

    Published on 2/2/2015
  • Amgen, Novartis biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Biosimilars Novartis Sandoz Inc. generics unit filed a motion in the U.S. District Court for the Northern …

    Published on 2/2/2015
  • Egenix cancer news

    Egenix Inc., Millbrook, N.Y. Business: Cancer Egenix filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. Egenix is developing small molecules that inhibit eukaryotic translation …

    Published on 2/2/2015
  • Moderna Therapeutics, Valera infectious news

    Moderna Therapeutics Inc., Cambridge, Mass. Valera LLC, Cambridge, Mass. Business: Infectious Moderna launched Valera to develop mRNA vaccines and therapeutics to treat and prevent viral, bacterial and parasitic …

    Published on 2/2/2015
  • N4 Pharma drug delivery news

    N4 Pharma Ltd., Chellaston, U.K. Business: Drug delivery Newco N4 Pharma launched two technology platforms -- Cocrys and Nuvac -- for drug reformulation and vaccine delivery. The Cocrys process creates co-crystals of …

    Published on 2/2/2015
  • NewLink, GlaxoSmithKline, J&J, Merck, Pfizer, Sanofi, Global Alliance for Vaccine Immunization infectious news

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Pfizer Inc.…

    Published on 2/2/2015
  • PharmAthene, Siga infectious news

    PharmAthene Inc. (NYSE-M:PIP), Annapolis, Md. Siga Technologies Inc. (NASDAQ:SIGA), New York, N.Y. Business: Infectious The Delaware Court of Chancery court ordered Siga to pay PharmAthene $194.6 million in a case …

    Published on 2/2/2015
  • Shire, Actavis generics, autoimmune news

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Actavis plc (NYSE:ACT), Dublin, Ireland Business: Generics, Autoimmune The U.S. Supreme Court granted a petition from Shire and remanded to a lower court Shires patent …

    Published on 2/2/2015
  • TransCelerate pharmaceuticals news

    TransCelerate BioPharma Inc., Philadelphia, Pa. Business: Pharmaceuticals Not-for-profit biopharma consortium TransCelerate added Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) and Novo Nordisk A/S (CSE:NVO; NYSE…

    Published on 2/2/2015
  • American Society of Clinical Oncology, SAP SE other news

    American Society of Clinical Oncology, Alexandria, Va. SAP SE (NYSE:SAP; Xetra:SAP), Walldorf, Germany Business: Other ASCO said software company SAP will provide computing infrastructure for the organizations …

    Published on 1/26/2015
  • J&J, Yale University other news

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Yale University, New Haven, Conn. Business: Other Johnson & Johnson agreed to make de-identified patient-level data from clinical trials of its medical devices and …

    Published on 1/26/2015
  • Teva, Momenta, Novartis autoimmune news

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Cambridge, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Autoimmune The U.S. …

    Published on 1/26/2015
  • Aveo Pharmaceuticals cancer news

    Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Cambridge, Mass. Business: Cancer Aveo eliminated its internal research function and reduced headcount by 40 (67%) to 20 to focus resources on advancing its clinical pipeline. …

    Published on 1/19/2015
  • Bavarian Nordic, J&J infectious news

    Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Infectious The EUs Innovative Medicines Initiative (IMI) awarded over 100 million ($118.2 million) to …

    Published on 1/19/2015
  • Cel-Sci, inVentiv Health cancer news

    Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. inVentiv Health Inc., Burlington, Mass. Business: Cancer Cel-Sci said an arbitration trial regarding its claim against inVentivs CRO, inVentiv Health Clinical, is scheduled for …

    Published on 1/19/2015
  • Cytori, U.S. Department of Health and Human Services gene/cell therapy, other news

    Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. U.S. Department of Health and Human Services, Washington, D.C. Business: Gene/Cell therapy, Other HHSs Biomedical Advanced Research and Development …

    Published on 1/19/2015
  • Daiichi Sankyo pharmaceuticals news

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Pharmaceuticals Daiichi will pay about $39 million, plus fees and costs, under a civil settlement with the U.S. government and participating states to …

    Published on 1/19/2015
  • Gilead infectious news

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious The Indian Patent Office rejected Gileads patent application covering HCV product Sovaldi sofosbuvir. The patent office issued a decision …

    Published on 1/19/2015
  • NewLink, Merck, U.S. Department of Health and Human Services infectious news

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced …

    Published on 1/19/2015
  • Cempra, U.S. Department of Health and Human Services infectious news

    Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious HHSs Biomedical Advanced Research and Development Authority (BARDA) exercised its first …

    Published on 1/12/2015
  • Cubist, Hospira infectious news

    Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Business: Infectious The U.S. District Court for the District of Delaware ruled that Cubists antibiotic Cubicin …

    Published on 1/12/2015
  • Kymab, Public Health England, University of Westminster, Wellcome Trust, Wellcome Trust Sanger Institute infectious news

    Kymab Ltd., Cambridge, U.K. Public Health England, Salisbury, U.K. University of Westminster, London, U.K. Wellcome Trust, London, U.K. Wellcome Trust Sanger Institute, Cambridge, U.K Business: Infectious Wellcome Trust…

    Published on 1/12/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993